PharmaShots | Incisive News in 3 Shots

Subscribe Now

adults

AbbVie-Skyrizi (risankizumab) Receives CHMP's Positive Opinion for the Treatment of Adults with Active Psoriatic Arthritis in the EU

AbbVie-Skyrizi (risankizumab) Receives CHMP's Positive Opinion for the Treatment of Adults with Active Psoriatic Arthritis in the...

October 18, 2021

$Sanofi's Sarclisa (isatuximab) Receives EC's Approval for adults with Relapsed and Refractory Multiple Myeloma$

Sanofi's Sarclisa (isatuximab) Receives EC's Approval for adults with Relapsed and Refractory Multiple Myeloma

April 19, 2021

Merck's Keytruda (pembrolizumab) Receives the EC's Approval in Adults & Pediatric patients with R/R cHL

Merck's Keytruda (pembrolizumab) Receives the EC's Approval in Adults & Pediatric patients with R/R cHL

March 18, 2021

Vir and GSK Provide Update on ACTIV-3 Trial of VIR-7831 in Hospitalized Adults with COVID-19

Vir and GSK Provide Update on ACTIV-3 Trial of VIR-7831 in Hospitalized Adults with COVID-19

March 4, 2021

Otsuka and Click Initiate Digital Study in Adults with Major Depressive Disorder

Otsuka and Click Initiate Digital Study in Adults with Major Depressive Disorder

February 26, 2021

Amgen Reports sNDA Submission of Otezla (apremilast) to The US FDA's for Adults with Mild to Moderate Plaque Psoriasis

Amgen Reports sNDA Submission of Otezla (apremilast) to The US FDA's for Adults with Mild to Moderate Plaque Psoriasis

February 23, 2021

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us